If you made any changes in Pure these will be visible here soon.

Personal profile


Profesor Mark Molloy’s expertise is centred on the development and application of proteomic analyses for addressing problems in the life-sciences. His expertise in the use of mass spectrometry as the core analytical technique supports collaborative research in many science and biomedical areas, where he has a particularly strong focus towards translational cancer research. A major theme has been development of new mass spectrometry workflows for quantitative targeted proteomic analyses. This has enabled investigation of important questions such as the molecular characterisation of colon, thyroid and pancreatic cancers, melanomas and some lung cancers. The information has been used to identify prognostic and predictive protein biomarkers. More recently, he has opened a new research direction to use high resolution mass spectrometry for pharmacokinetic monitoring of cancer drug levels in cancer patients and is explore analysis from dried blood spots.

Mark’s leadership and international standing in the application of proteomics is evidenced by outstanding grant success (career total $42.9M), publications (>150), Scopus citations (>5,000) and HDR student completions (14). He was Director of the Australian Proteome Analysis Facility 2010-18 where his team provided expertise and world-class proteomic infrastructure to ~100 external academic and industry end-users each year.  

Mark completed his PhD in proteomic sciences at Macquarie University under the supervision of Keith Williams before conducting post-doctoral research at the University of Michigan Medical School in Ann Arbor, USA. He then worked in the US pharmaceutical industry at Pfizer Inc for four years. He returned to Australia to carry out a National Health and Medical Research Council career development award fellowship on colorectal cancer (CRC) biomarker proteins before becoming Director of APAF.

He is an Honorary Professor in the Department of Molecular Sciences and Professor at The University of Sydney.



External positions

Professor, University of Sydney

Mar 2018 → …

Fingerprint Dive into the research topics where Mark Molloy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 20 Similar Profiles
Proteomics Medicine & Life Sciences
Proteins Medicine & Life Sciences
Mass Spectrometry Medicine & Life Sciences
Proteome Medicine & Life Sciences
Electrophoresis Chemical Compounds
Mass spectrometry Chemical Compounds
Biomarkers Chemical Compounds
Membrane Proteins Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2006 2020

High content oncoproteomics for improved prognostication and treatment response

Packer, N., Molloy, M., Engel, A., Clarke, S., Gill, A., Samra, J., Baker, M. & Andersen, M.

1/07/17 → …

Project: Research

Frontotemporal Dementia
Motor Neuron Disease

Research Outputs 1997 2019

Drug Monitoring

Examining cellular responses to kinase drug inhibition through phosphoproteome mapping of substrates

Bucio-Noble, D., Semaan, C. & Molloy, M. P., 2019, Systems chemical biology: methods and protocols. Ziegler, S. & Waldmann, H. (eds.). New York: Humana Press, p. 141-152 12 p. (Methods in Molecular Biology; vol. 1888).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

Mass Spectrometry
Statistical Data Interpretation
Pharmaceutical Preparations

Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

Arasaratnam, M., Crumbaker, M., Bhatnagar, A., McKay, M. J., Molloy, M. P. & Gurney, H., Jul 2019, In : Cancer Chemotherapy and Pharmacology. 84, 1, p. 139-146 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Prostatic Neoplasms
Pharmaceutical Preparations
Drug Therapy

iSwathX: an interactive web-based application for extension of DIA peptide reference libraries

Noor, Z., Wu, J. X., Pascovici, D., Mohamedali, A., Molloy, M. P., Baker, M. S. & Ranganathan, S., 1 Feb 2019, In : Bioinformatics. 35, 3, p. 538-539 2 p.

Research output: Contribution to journalArticleResearchpeer-review

Peptide Library
Mass Spectrometry

Pathogenic mutation in the ALS/FTD gene, CCNF, causes elevated Lys48-linked ubiquitylation and defective autophagy.

Lee, A., Rayner, S. L., Gwee, S. S. L., De Luca, A., Shahheydari, H., Sundaramoorthy, V., Morsch, M., Hogan, A., Don, E., Williams, K., Yerbury, J. J., Blair, I., Atkin, J. D., Molloy, M. P. & Chung, R. S., 8 Feb 2019. 1 p.

Research output: Contribution to conferenceAbstractResearchpeer-review